Kyowa Kirin Co., Ltd. (FRA:KY4)

Market Cap	6.66B -4.9%
Revenue (ttm)	2.78B +3.2%
Net Income	397.67M +41.8%
EPS	0.76 +42.6%
Shares Out	n/a
PE Ratio	16.76
Forward PE	n/a
Dividend	0.35 (2.79%)
Ex-Dividend Date	Dec 29, 2025

Volume	n/a
Open	12.30
Previous Close	12.60
Day's Range	12.30 - 12.30
52-Week Range	11.70 - 15.70
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 7, 2026

About Kyowa Kirin

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodular...

• Industry: Pharmaceutical Preparations
• Founded: 1949
• Employees: 5,161
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: KY4

Financial Performance

In 2025, Kyowa Kirin's revenue was 496.83 billion, an increase of 0.26% compared to the previous year's 495.56 billion. Earnings were 67.04 billion, an increase of 11.98%.

Financial numbers in JPY